Clinical trial
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis
NCT00071214 is registered in ClinicalTrials.gov with Nabi Biopharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis
- Lead sponsor
- Nabi Biopharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2003
- Completion date
- September 30, 2005
- Enrollment
- 3,600
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.